A detailed history of Carlson Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Carlson Capital Management holds 1,575 shares of ABBV stock, worth $276,538. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,575
Holding current value
$276,538
% of portfolio
0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $258,048 - $313,944
1,575 New
1,575 $311,000
Q4 2023

Jan 16, 2024

BUY
$137.6 - $154.97 $155,075 - $174,651
1,127 Added 55.06%
3,174 $491,000
Q3 2023

Nov 21, 2023

SELL
$133.59 - $154.65 $20,439 - $23,661
-153 Reduced 6.95%
2,047 $305,000
Q2 2023

Jul 24, 2023

BUY
$132.51 - $164.9 $15,503 - $19,293
117 Added 5.62%
2,200 $296,000
Q1 2023

Apr 17, 2023

SELL
$144.61 - $166.54 $12,581 - $14,488
-87 Reduced 4.01%
2,083 $331,000
Q4 2022

Feb 03, 2023

SELL
$138.31 - $165.87 $53,802 - $64,523
-389 Reduced 15.2%
2,170 $350,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $1,878 - $2,155
14 Added 0.55%
2,559 $343,000
Q2 2022

Jul 18, 2022

SELL
$137.62 - $174.96 $24,358 - $30,967
-177 Reduced 6.5%
2,545 $390,000
Q1 2022

May 24, 2022

BUY
$131.98 - $163.75 $74,040 - $91,863
561 Added 25.96%
2,722 $441,000
Q4 2021

Jan 14, 2022

BUY
$107.43 - $135.93 $2,256 - $2,854
21 Added 0.98%
2,161 $293,000
Q3 2021

Oct 12, 2021

BUY
$106.4 - $120.78 $7,873 - $8,937
74 Added 3.58%
2,140 $231,000
Q2 2021

Jul 12, 2021

BUY
$105.21 - $117.21 $4,103 - $4,571
39 Added 1.92%
2,066 $233,000
Q1 2021

Apr 12, 2021

BUY
$102.3 - $112.62 $207,362 - $228,280
2,027 New
2,027 $219,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Carlson Capital Management Portfolio

Follow Carlson Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carlson Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Carlson Capital Management with notifications on news.